2021 CMSC Annual Meeting

Tag: Cleveland

Poster-Symptom Management

Sources of Cannabis Information and Medical Guidance Among People with Multiple Sclerosis: Narcoms Survey Results

Background: The North American Research Committee on Multiple Sclerosis (NARCOMS) registry is a voluntary, self-report registry for people...

Read More

Poster-Rehabilitation Poster

Characterizing the Relationship between Neurological/Mental Health and Physical Activity Levels in Persons with Multiple Sclerosis

Background: Physical activity is one way that persons with multiple sclerosis (MS) (PwMS) can manage disease symptoms and progression....

Read More

Poster-Relapse Therapy

Results from a Multicenter, Randomized, Double Blind, Placebo-Controlled Study of Repository Corticotropin Injection for Relapsing-Remitting Multiple Sclerosis

Background: Patients with relapsing-remitting multiple sclerosis (RRMS) may experience acute relapses that are nonresponsive (20-35%) to...

Read More

Poster-Quality of Life and Outcomes

Factors Associated with Stigma in People with Multiple Sclerosis.

Background: Social stigma is a common experience among persons with multiple sclerosis (PwMS), and it may impact daily functioning, quality...

Read More

Poster-Quality of Life and Outcomes

An Update on Participants in the Iconquerms Network.

Background: iConquerMS is a multiple sclerosis (MS) participant-powered research network (PPRN), dedicated to engaging people affected by...

Read More

Poster-Quality of Life and Outcomes

Gratitude, Perceived Stress, and Quality of Life Among Patients with MS

Background: Multiple sclerosis (MS) is characterized by an unpredictable course of neurological symptoms that are thought to be exacerbated...

Read More

Poster-Epidemiology and Genetics

Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry

Background: An estimated 85% of persons with multiple sclerosis (MS) present with relapsing-remitting (RRMS) disease. There are few large...

Read More

Poster-Disease-modifying Therapy

Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls

Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...

Read More

Poster-Disease-modifying Therapy

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...

Read More

Poster-Disease-modifying Therapy

Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study

Background: In the Phase 3 EXPAND trial siponimod, a selective S1P receptor modulator, significantly reduced risk of 3-month and 6-month...

Read More